CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Clinical trial NCT04493164 · RECRUITING

Trial details

NCT number: NCT04493164
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia With Gene Mutations Myelodysplastic Syndrome Myeloproliferative Neoplasm Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia

Start date: 2020-12-30
Primary completion: 2028-06-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.